The GADD45c protein is a potential tumor suppressor whose expression is reduced in several tumors. However, very little is known about the regulation of its expression. We have determined that the most relevant region of its promoter lies between nucleotides À112 and À54, relative to the transcription start site. Putative Oct and NF-Y elements were found in this region and factors belonging to these families interacted with these elements in vitro and with the promoter in vivo. Mutation of these elements reduced the basal activity of the promoter, suggesting that both sites are essential for basal expression. These factors interact with chromatin modifying proteins and we found that histone deacetylase 1 or silencing mediator for retinoid and thyroid hormone receptor overexpression reduced the basal activity of the promoter. In contrast, forced expression of the histone acetylase protein PCAF or cell treatment with the HDAC inhibitor trichostatin A increased GADD45c mRNA levels and induced GADD45c promoter activity through its Oct and NF-Y elements. Moreover, ectopic expression of a dominantnegative version of NF-YA strongly inhibited trichostatin A-induced activation of the promoter. Our data strongly suggest that inhibition of deacetylase activity could potentially be used for treatment of tumors where GADD45c expression is reduced.
Introduction
The GADD45 family of genes, including GADD45a, GADD45b and GADD45g, is induced by genotoxic stress and a subset of cytokines in many different cell types . GADD45g (CR6/OIG37/GRP17) expression is induced in myeloid leukemia cells in response to genotoxic stress or interleukin (IL)-6 (Takekawa and Saito, 1998; Zhang et al., 1999) , in hemangioblasts in response to oncostatin M (Nakayama et al., 1999) , in neurons in response to nerve growth factor depletion (Kojima et al., 1999) and in T cells in response to IL-2 or IL-12 plus IL-18 (Beadling et al., 1993; Lu et al., 2004) .
Gadd45 proteins have very similar amino acid sequences (Takekawa and Saito, 1998; Zhang et al., 1999) and have been implicated in cell cycle arrest Zhang et al., 1999; Jin et al., 2002) , DNA repair (Smith et al., 2000) , innate immunity (Lu et al., 2001; Yang et al., 2001) , maintenance of genomic stability (Hollander et al., 1999) and apoptosis (Takekawa and Saito, 1998; Zhang et al., 1999 Zhang et al., , 2001 . Gadd45 proteins display a complex array of physical interactions with cellular proteins involved in cell cycle regulation and the response to extrinsic stress, including p21, Cdc2/ cyclinB1 and components of the JNK and p38 stressinduced kinase pathways . In particular, Gadd45g regulates apoptosis in several cell types (Takekawa and Saito, 1998; Zhang et al., 2001; Chung et al., 2003) and cytokine production in T cells (Lu et al., 2001) . Moreover, Gadd45g negatively regulates progression through the cell cycle. This effect is likely mediated by its capacity to inhibit cyclinB1-cdk1 activity (Vairapandi et al., 2002) .
Gadd45g expression is reduced in several tumors, such as pituitary adenomas (Zhang et al., 2002) , anaplastic thyroid cancer (Chung et al., 2003) , hepatocellular carcinoma (Sun et al., 2003) and lymphoma and nasopharyngeal carcinoma cell lines (Ying et al., 2005) in comparison to normal tissues. A low Gadd45g expression could be functionally relevant to tumor growth because transient transfection of Gadd45g induced growth arrest and/or apoptosis in a number of tumor cell lines (Takekawa and Saito, 1998; Zhang et al., 2001 Zhang et al., , 2002 Chung et al., 2003; Jiang and Wang, 2004; Ying et al., 2005) . These observations suggest that GADD45g can be considered as a functional tumor suppressor gene. Although several studies have addressed the transcriptional regulation of the GADD45a and b genes (Zhan et al., 1994; Constance et al., 1996; Marhin et al., 1997; De Smaele et al., 2001; Jin et al., 2001; Takahashi et al., 2001) , very little is known about the regulation of the GADD45g gene. In fact, to the best of our knowledge, there is only a single study addressing GADD45g gene regulation where it was suggested that transcription factors C/EBPb and d might be involved in GADD45g promoter activation during differentiation of M1 cells (Jung et al., 2000) .
A general mechanism of gene regulation relies on the interactions of transcription factors with co-activators that contain histone acetyltransferase (HAT) activity and co-repressors that contain histone deacetylase (HDAC) activity (Berger, 2002) . HDAC inhibitors, such as trichostatin A (TSA; Sigma, Tres Cantos, Madrid, Spain), induce many genes coding for proteins involved in cell cycle control, including GADD45a and GADD45b (Della-Ragione et al., 2001; Chen et al., 2002; Hirose et al., 2003) , and stop tumor growth by eliciting either cell cycle arrest or apoptosis in tumor cells (Johnstone, 2002) .
Since GADD45g expression is reduced in tumors and its forced expression has tumor-suppressive properties, a detailed knowledge of the molecular mechanisms regulating its expression might help to develop new antitumor therapeutic strategies. We therefore analysed the mechanisms of GADD45g transcriptional regulation. Our results indicate that functional Oct and NF-Y elements are essential for the promoter activity, that GADD45g promoter can be regulated through histone acetylation/deacetylation, and that GADD45g expression can be readily induced in tumor cells by HDAC inhibitors possibly through the NF-Y and Oct elements of its promoter.
Results
Deletion and point mutation analysis of the murine GADD45g promoter To gain insight into the molecular mechanisms regulating GADD45g expression, we first identified the motifs required for basal activity of the murine GADD45g promoter. To this end, a set of 5 0 serially deleted promoter fragments, spanning from nucleotides À818 to þ 15 according to the transcription start site (Balliet et al., 2003) , were cloned upstream from the luciferase gene in pGL3-Basic. The resulting reporter constructs were transiently transfected in NIH3T3 cells and the luciferase activity was assayed for each construct. As shown in Figure 1 , although the promoter activity decreased when the region À818 to À112 was deleted, an almost complete ablation of its activity was achieved only upon deletion of the À112 to À54 region. These results suggest that although elements within the À818 to À112 can contribute to this promoter regulation, the region between À112 and À54 is essential for its activity.
A search for putative transcription factor binding sites using MatInspector (Cartharius et al., 2005) revealed the presence in the À112 to À54 region of potential Oct (ATTTGCAT), and NF-Y (CCAAT) binding sites. Site-directed mutagenesis was used to generate mutated versions of the À818 construct devoid of the Oct (Octm) and NF-Y (NFYm) sites, individually or combined. As shown in Figure 2 , mutation of the individual sites or their combination decreased the activity to 35-50% of the wild-type promoter activity, suggesting that these elements significantly contribute to promoter activation. Identification of proteins interacting with the Oct and NF-Y sites of the murine GADD45g promoter Electrophoretic mobility shift assays (EMSAs) were performed using probes containing either the Oct (nucleotides À116 to À93) or the NF-Y site (nucleotides À92 to À69). A major DNA-protein complex was detected with each probe whose formation was eliminated by an excess of unlabeled self Oct or NF-Y competitor probe (Figures 3a and b) , indicating that formation of these complexes was specific. These factors appear to correspond to Oct-1 and NF-Y factors since addition of an excess of oligonucleotides known to bind either Oct (Control-Oct) or NF-Y (Control-NF-Y) proteins also ablated formation of the corresponding complexes, while an irrelevant oligonucleotide (E2F-1A) had no effect (Figure 3a) . Moreover, anti-NF-YB, but not anti-Maz addition, abolished formation of the DNA-protein complex observed with the NF-Y probe ( Figure 3a ). An anti-Oct-1, but not an anti-Maz antibody, partially decreased formation of the DNAprotein complex observed with the Oct probe and presented a supershifted band ( Figure 3a ). Employing nuclear extracts from HEK293-T cells transfected with an Oct-1 expression plasmid, anti-Oct-1 addition caused a supershift of the majority of the complex observed with the Oct probe, indicating that this probe can actually bind Oct-1 and that the antibody used in these experiments works well in these assays. Because the antiOct-1 antibody had only a partial effect employing NIH3T3 extracts, it is likely that other members of the Oct family might also interact with the GADD45g Oct element in vitro.
To directly test whether Oct-1 and NF-Y were associated with the murine GADD45g promoter in vivo, chromatin immunoprecipitation (ChIP) assays were performed with anti-Oct-1, anti-NF-YB or Rabbit anti-mouse IgG antibodies. The products of PCR reactions performed with DNA eluted from the immunoprecipitates are shown in Figure 3b . A product containing the Oct and NF-Y sites was specifically amplified with oligonucleotides flanking the proximal GADD45g promoter (Specific in Figure 3b ) employing both anti-Oct-1 and anti-NF-YB immunoprecipitates, but not when the anti-mouse IgG immunoprecipitate was used. In contrast, no product was amplified with oligonucleotides flanking a region about 3000 nucleotides upstream from the GADD45g transcription initiation site (Control in Figure 3b ) using any of the immunoprecipitates, while these oligonucleotides amplified the product from input chromatin DNA. These results show that Oct-1 and NF-Y can bind to the murine GADD45g proximal promoter in vivo.
Co-transfection assays were performed to confirm the involvement of Oct-1 and NF-Y in the regulation of the murine GADD45g promoter. The luciferase reporter plasmids used were either the deleted À220 to þ 15 promoter construct, which contains the Oct and NF-Y sites, or a mutated version of this construct devoid of these sites (À220OctmNFYm). As shown in Figure 4 , Oct-1 or NF-YA overexpression slightly increased the activity of the À220 to þ 15 reporter, but not that of the À220OctmNFYm construct or that of the promoterless reporter (pGL3-B). However, co-transfection of both Oct-1 and NF-YA strongly increased the activity of the À220 to þ 15 reporter, but barely affected the activity of the pGL3-B or the À220OctmNFYm reporters ( Figure 4) .
Altogether, these results show that transcription factors Oct-1 and NF-Y can interact with the murine GADD45g promoter in vivo and that they might be important for the basal transcriptional activity of the promoter.
Role of co-repressors and co-activators in the regulation of the murine GADD45g promoter NF-Y and Oct-1 can interact with HAT-containing coactivator complexes and HDAC-containing co-repressor complexes (Nagy et al., 1997; Mantovani, 1999; Kakizawa et al., 2001; Park et al., 2002; Peng and Jahroudi, 2003; Huang et al., 2005) . We therefore assessed the contribution of these factors to GADD45g promoter activity regulation. Silencing mediator for retinoid and thyroid hormone receptors (SMRT) interact with Oct-1 and acts as a transcriptional co-repressor (Kakizawa et al., 2001) . To analyse the possible role of Oct-1-associated SMRT in the regulation of the GADD45g promoter, a SMRT expression plasmid was co-transfected with the À818 to þ 15 promoter reporter plasmid. As shown in Figure 5a , SMRT co-transfection resulted in a dose-dependent inhibition of transcriptional activity.
Because SMRT co-repressor activity can be exerted through its presence in a macromolecular complex containing the HDAC1 (Nagy et al., 1997) and NF-Y inhibits von Willebrand factor promoter activity through recruitment of HDACs (Peng and Jahroudi, 2003) , we investigated the involvement of HDAC1 in the regulation of the GADD45g promoter. To this end, an HDAC1 expression plasmid was co-transfected with the À818 to þ 15 promoter reporter plasmid. As shown in Figure 5b , HDAC1 co-transfection reduced GADD45g promoter activity almost twofold, as compared to cotransfection with the control vector or HDAC3 expression plasmid.
NF-Y recruits the histone acetylase PCAF to promoters (Park et al., 2002; Huang et al., 2005) . The participation of PCAF in the regulation of the GADD45g promoter was addressed by co-transfecting a PCAF expression plasmid with the À818 to þ 15 promoter reporter plasmid. As shown in Figure 5c , PCAF co-transfection resulted in a dose-dependent induction of GADD45g promoter activity.
Transcriptional induction of the GADD45g gene by TSA The results described above suggest that HATs and deacetylases (HDACs) can participate in the regulation of the murine GADD45g promoter. To confirm this hypothesis, we used the HDAC inhibitor TSA. Treatment of NIH 3T3 cells with TSA for 24 h increased GADD45g mRNA expression levels in a dose-dependent manner, as determined by northern blot analysis (Figure 6a) . Because TSA causes G 1 phase arrest in the human T-cell leukemia cell line, Jurkat (Yokota et al., 2004) and the increase of GADD45g expression is able to induce growth arrest, we assessed whether Jurkat cells treatment with TSA could induce GADD45g mRNA expression in these cells. As shown in Figure 6b , GADD45g mRNA expression levels, but not those of the g-actin mRNA, were notably increased in these cells following treatment with TSA. These results suggest that G 1 -phase arrest induction by TSA in the leukemic line Jurkat might be mediated, at least in part, through induction of GADD45g expression. To rule out that toxicity caused by TSA treatment had a major role in GADD45g expression regulation, propidium iodide staining was used to assess DNA content by flow cytometry analysis. As shown in Figure 7 , none of the different TSA doses employed in our experiments caused the appearance of apoptotic cells with a sub-G 1 DNA content. Oct and NF-Y sites participate in the induction of the GADD45g promoter by TSA To analyse the possible contribution of Oct and NF-Y sites to GADD45g promoter induction by TSA, the transcriptional activity of different site-directed mutant reporters was analysed in NIH3T3 cells untreated or treated with 0.1 mM TSA. Wild-type Oct and NF-Y elements appear to be essential for GADD45g promoter activation by TSA because mutation of both the Oct and NF-Y sites ablated TSA induction of the À818 to þ 15 promoter (Figure 8a ). In fact, similar results were obtained with the promoterless luciferase vector pGL3-B (Figure 8a ). Mutation of either site alone did not inhibit promoter induction by TSA (Figure 8a ). The transcriptional activity of a minimal version of the promoter, spanning from nucleotides À220 to þ 15 and containing the Oct and NF-Y sites, was also strongly induced by TSA (Figure 8b ). This induction was dependent on the Oct and NF-Y sites, since mutation of both sites reduced TSA induction to almost 10% to that of the wild-type minimal promoter (Figure 8b ). These results indicate that the Oct and NF-Y sites are essential for the induction of the murine GADD45g promoter by TSA. The role of NF-Y transcription factor in TSA induction of the murine GADD45g promoter was further analysed by using the dominant-negative NF-YA expression plasmid, NF-YAm29, which is devoid of DNA-binding activity (Mantovani et al., 1994) . Cotransfection of NF-YAm29, but not that of the control plasmid, with the À818 to þ 15 promoter reporter resulted in a dose-dependent inhibition of TSA induction (Figure 9 ), further implicating NF-Y in the TSAinduced activation of the GADD45g promoter.
Discussion
Despite the importance of GADD45g as a tumor suppressor, almost nothing was known about the mechanisms governing its expression. It was only known that GADD45g promoter is induced by IL-6 or during M1 cells differentiation, likely through a noncanonical C/EBP binding element (Jung et al., 2000) . Notably, very little is known about the mechanisms eliciting to its loss of expression in tumors. The murine GADD45g promoter shares some structural features with the murine GADD45a promoter, namely Oct and NF-Y putative binding sites. Mutation of these sites in the human GADD45a promoter decreases its basal activity (Hirose et al., 2003) . Similarly, we have shown that mutation of either the Oct or NF-Y sites decreases the murine GADD45g promoter basal activity and that expression of Oct-1 and NF-YA increases its activity. We have also shown that these factors interacted with these sites in vitro and with the GADD45g promoter in vivo. Therefore, the Oct and NF-Y sites shared by the human GADD45a and murine GADD45g promoters appear to be relevant for their transcriptional activities. Because deletion of the À818 to À112 partially decreased the basal activity of the murine GADD45g promoter, it is likely that this region also contains positive regulatory elements. In fact, MatInspector identified potential transcription factor binding sites in this region, such as ATF6, NFAT, Nur77 and myc. Besides Oct and NF-Y binding sites, the À112 to À54 region also contains a TATA box and potential binding sites for additional factors such as or C/EBP, ZF5 and NF-I. These sites might account for the basal activity of the À818 to þ 15 reporter devoid of the Oct and NF-Y sites (Figure 2) . However, the Oct and NF-Y sites in the À112 to À54 region are the most critical sites for induction of the promoter by the HDAC inhibitor TSA (Figure 8 ).
Since Oct-1 and NF-Y can interact with HATcontaining co-activator complexes and HDAC-containing co-repressor complexes (Nagy et al., 1997; Mantovani, 1999; Kakizawa et al., 2001; Park et al., 2002; Peng and Jahroudi, 2003; Huang et al., 2005) , we studied the possible role of SMRT, HDAC1, and PCAF in the regulation of the murine GADD45g promoter. SMRT or HDAC1, but not HDAC3, ectopic expression reduced GADD45g promoter activity, while forced expression of PCAF increased it. These results suggest that regulation of histone acetylation/deacetylation levels is essential for murine GADD45g promoter control. It has been proposed that SMRT-induced repression could be exerted through its presence in a complex containing HDAC1. However, we have found that SMRT-induced repression of GADD45g promoter activity is stronger than that induced by HDAC1. These results might suggest that other members of the HDAC family might be involved in SMRT-induced repression. Alternatively, SMRT might elicit GADD45g promoter repression through some other mechanism independent of HDAC activity.
Although HAT and HDAC activities play a general role in the regulation of gene activity, only a small proportion of genes is susceptible to regulation by HDAC inhibitors (Mariadason et al., 2000) . A large proportion of HDAC inhibitor-regulated genes encode for proteins involved in cell cycle control (Johnstone, 2002) . In this study, we show that the murine GADD45g gene is induced by the HDAC inhibitor TSA and that the Oct and NF-Y sites present in the murine GADD45g proximal promoter are essential for its regulation by TSA. Mutation of individual Oct or NF-Y sites in the murine GADD45g promoter did not hamper its activation by TSA, suggesting that either site is sufficient to mediate activation by TSA. This inhibitor has been previously shown to upregulate GADD45a mRNA levels in human colon carcinoma and osteosarcoma cells (Della-Ragione et al., 2001; Chen et al., 2002; Hirose et al., 2003) and GADD45b mRNA levels in human colon carcinoma cells (Chen et al., 2002) . Because we have not directly investigated whether GADD45a or GADD45b expression is induced by TSA in NIH3T3 cells, we cannot rule out that this inhibitor might also induce the expression of these genes in NIH3T3 or Jurkat cells. In the human GADD45a promoter, two sets of Oct and NF-Y sites contribute to its activation by TSA (Hirose et al., 2003) . However, the human GADD45b proximal promoter contains NF-Y sites but no Oct site, as predicted by MatInspector analysis (Cartharius et al., 2005) . In consequence, although the three GADD45 genes are induced by TSA, the molecular mechanism underlying this induction may be different in the GADD45b gene, as compared to the GADD45a and GADD45g genes.
Oct sites are present in the promoters of cell cycleregulated genes such as histone 2B (Hinkley and Perry, 1992) and cyclin D1 (Brockman and Schuler, 2005) . In addition, the binding of NF-Y to several cell cycle control genes is strictly regulated during the different phases of the cell cycle (Caretti et al., 2003) . Thus, the involvement of Oct and NF-Y sites in the regulation of the GADD45a and GADD45g genes by TSA, a growtharrest inducer (Mariadason et al., 2000) , constitutes another example of Oct and NF-Y-mediated, cell cycledependent regulation of gene expression.
The mechanisms that underlie the participation of the Oct and NF-Y sites in the TSA-induced activation of the murine GADD45g promoter remain unknown. A possible mechanism is that TSA alters the DNA-binding ability of Oct-1 or NF-Y. In fact, it has been reported that the binding activity of Oct-1 to the HLA-DRA promoter is greatly reduced by TSA treatment (Osborne et al., 2001) . However, EMSAs showed that TSA treatment did not change the affinity of nuclear factors for the NF-Y or Oct sites in the murine GADD45g promoter (unpublished observations). This agrees with the lack of effect of TSA on the affinity of NF-Y or Oct-1 for their sites in the human GADD45a promoter (Hirose et al., 2003) . Alternatively, TSA treatment may affect the interaction of Oct-1 with SMRT-HDAC1, and/or the interactions of NF-Y with HDAC1 or PCAF. In this regard, TSA releases HDAC2 from the histone-DNA complex at the INK4d promoter (Yokota et al., 2004) . Further experiments will be required to definitely establish the molecular mechanism involved in GADD45g promoter activation by TSA.
GADD45g expression is reduced in pituitary adenomas, anaplastic thyroid cancer and hepatocellular carcinoma, and lymphoma and nasopharyngeal carcinoma cell lines (Zhang et al., 2002; Chung et al., 2003; Sun et al., 2003; Ying et al., 2005) and forcing of its expression blocks proliferation of several cancer cell lines (Takekawa and Saito, 1998; Zhang et al., 2001 Zhang et al., , 2002 Chung et al., 2003; Jiang and Wang, 2004; Ying et al., 2005) . In particular, TSA causes G 1 phase arrest in the human T-cell leukemia cell line, Jurkat (Yokota et al., 2004) . The mechanisms eliciting loss of GADD45g expression in tumors are poorly characterized. Our results showing that TSA treatment induces GADD45g expression in Jurkat cells, but not in ARO thyroid or MCF-7 mammary cancer cell lines (Figure 6b and unpublished observations) suggest that histone deacetylation might account for the mechanism involved in GADD45g loss of expression in some tumors. Furthermore, our results suggest that it is very likely that the TSA anti-proliferative effect in some cancer cell lines is mediated, at least in part, by the induction of GADD45g expression. Our results might therefore provide the basis for the development of better therapeutic approaches based on the induction of this tumor suppressor gene.
Materials and methods

Plasmids
A DNA fragment containing nucleotides between À818 and þ 15 of the murine GADD45g gene (Balliet et al., 2003) was amplified by PCR from a genomic clone provided by Dr J Ihle (St Jude Children's Research Hospital, Memphis, TN, USA) and cloned into the pGL3-Basic vector (Promega, Madison, WI, USA). The resulting reporter plasmid (À818) was used to generate deleted versions of the promoter reporter in pGL3-Basic. The À482 and À220 reporters (nucleotides between À482 or À220 and þ 15) were generated by using two internal PstI sites. The À112 and À54 reporters (nucleotides between À112 or À54 and þ 15) were generated by PCR. Point mutations that eliminate the Oct or NF-Y sites (named Octm or NFYm) were introduced in the À818 or À220 reporters by using PCR or the Qickchange mutagenesis kit (Stratagene, Amsterdam, The Netherlands). The upper-strand oligonucleotides used were Octm, 5 0 -CAGGCCTGCCGCCTCACTTCATG CAGAAAGCGGGCGCTGG-3 0 and NFYm, 5 0 -AAGCGG GCGCTGGCCCATGGGAGTGCAGCC-3 0 . The mutations correspond to the underlined sequences and their presence in the reporters was verified by sequencing. The expression vectors and their providers were pCG-Oct-1, Dr W Herr, Universite´de Lausanne, Switzerland; pCMX-SMRT, pCMX-HDAC1 and pCMX-HDAC3, Dr RM Evans, The Salk Institute for Biological Studies, San Diego, CA, USA; pCX-PCAF, Dr T Kouzarides, The Gurdon Institute, Cambridge, UK and pSG5-NF-YAm29, Dr R Mantovani, Universita`di Milano, Italy.
Cell culture, transient transfection and reporter assay NIH3T3 fibroblasts were maintained in Dulbecco's modified Eagle's medium supplemented with 10% calf serum (Sigma). Cells (6 Â 10 4 ) were seeded in 24-well plates and transfected with luciferase reporter plasmids (25-125 ng), expression vectors (25-200 ng), pcDNA3-b-gal, LipofectAMINE and Plus reagent (Invitrogen, Prat de Llobregat, Barcelona, Spain). In some experiments, NIH3T3 fibroblasts were incubated with the HDAC inhibitor TSA (Sigma). After 24 h, cells were harvested into 100 ml of passive lysis buffer (Promega), and luciferase activity was measured according to the manufacturer's instructions. The luciferase activity was normalized to the protein concentration of the lysate, as determined with the Bradford protein assay (Bio-Rad, Hercules, CA, USA), and to the b-galactosidase activity.
Nuclear extracts and EMSA Nuclear extracts from NIH3T3 cells or HEK293-T cells transiently transfected with either the pCG-Oct-1 or the empty expression plasmid were prepared as described previously (Campanero et al., 1999) . EMSAs were performed with the complementary oligonucleotides (Invitrogen):
The Control-NFY-double-stranded oligonucleotide has been reported to bind specifically to NF-Y (Inoue et al., 1999) . The E2F1-A double-stranded oligonucleotide corresponds to the distal E2F element in the E2F1 promoter (Campanero et al., 2000) . The Control-Oct oligonucleotide, double stranded, that contains the binding site for Oct2A was obtained from Roche (Barcelona, Spain). The sequence of its upper strand is: 5 0 -GATCCAGATGCAAATACGGATCCA. The oligonucleotides were mixed at an equimolar ratio in 10 mM Tris (pH 7.5), 50 mM NaCl, heated to 65 1C and annealed by slow cooling to room temperature (RT). Double-stranded oligonucleotides (100 ng) were labeled with T4 polynucleotide kinase. The antibodies used were anti-MAZ (sc-13484 Â , Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Oct-1 (05-240, Upstate, Charlottesville, VA, USA) and anti-NF-YB (sc-13045 Â , Santa Cruz Biotechnology). Binding reactions and gel electrophoresis were performed as described previously (Campanero et al., 1999) .
ChIP assay
Cells were treated with 10 mM dimethyl adipimidate and 0.25% dimethylsulfoxide in phosphate-buffered saline (PBS) for 45 min at RT and subsequently treated with formaldehyde at a final concentration of 1% for 15 min at RT. Sonication was performed to achieve an average DNA length of 200-800 bp. Crosslinked chromatin was precleared with Protein A-Sepharose beads (preincubated with sonicated salmon sperm DNA, bovine serum albumin (BSA) and normal rabbit serum) and immunoprecipitated with Rabbit anti-mouse IgG (M7023, Sigma), anti-Oct-1 (05-240, Upstate) or anti-NF-YB (sc-13045 Â , Santa Cruz Biotechnology). Immunoprecipitated complexes were collected with Protein A-Sepharose beads preincubated with sonicated salmon sperm DNA and BSA. The beads were washed and eluted, and DNA was extracted from the eluates according to the ChIP Assay Kit protocol (Upstate). DNA was subjected to PCR using either specific primers that amplified a product corresponding to positions -310 to þ 46 of the murine GADD45g gene (5 0 -TTCCAGT ATCGTATCAGCAAACAAC-3 0 and 5 0 -GGTAAAGATTCC CAGAGTCCGATGC-3 0 ) or control primers that amplified a product corresponding to positions -2943 to À2680 of the same gene (5 0 -CAAGTAGCTGGGATTCTAGGTTTTA-3 0 and 5 0 -AACCCCATATTATCCGGTGGCTACA-3 0 ). The amplified DNA products were separated on 1% agarose gel and visualized with ethidium bromide.
RNA preparation and northern blot analysis NIH3T3 fibroblasts were incubated with the HDAC inhibitor TSA for 24 h and the cells were harvested and lysed in TriReagent (Sigma). Total RNA was extracted according to the manufacturer's protocol and 20 mg were subjected to electrophoresis in an agarose-formaldehyde gel and transferred to Zeta-Probe membranes (Bio-Rad). Membranes were hybridized with the [a-
32 P]dCTP probe for murine GADD45g
(provided by Dr J Ihle), stripped and reprobed for g-actin mRNA.
Cell cycle analysis Asynchronous NIH3T3 cell cultures were exposed to TSA for 24 h and harvested from culture dishes. After washing with PBS, cells were fixed in 70% ethanol, treated with RNAse A and the nuclei were stained with propidium iodide. Their fluorescence was analysed by flow cytometry using a FACScan (Becton Dickinson).
